MCL Literature Feed

This case report describes a rare intrasinusoidal presentation of pleomorphic MCL, highlighting a critical diagnostic pitfall that can mimic intravascular large B-cell lymphoma.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

The t(11;14) translocation in MCL upregulates entire gene regulons across the chromosome arm via long-range chromatin interactions, revealing a novel mechanism of widespread oncogenic dysregulation beyond just CCND1.

A novel dual PI3K/HDAC inhibitor demonstrates enhanced pro-apoptotic activity in lymphoma cells, presenting a potential new preclinical strategy for MCL by simultaneously targeting two key pathways.

This case report demonstrates that secondary prostatic MCL can mimic prostate cancer, and transurethral resection can effectively manage resultant urinary retention, highlighting a rare extramedullary presentation.

This case report describes a rare presentation of mantle cell lymphoma with involvement of the entire gastrointestinal tract, highlighting diverse endoscopic findings beyond typical nodular or polypoid lesions.

This review characterizes the rare transformation of MCL into aggressive Burkitt lymphoma, a distinct form of Richter's syndrome, highlighting its unique pathogenesis, clinical features, and poor prognosis.

A preclinical mouse study reveals acalabrutinib alleviates fatty liver disease by regulating bile acid metabolism, suggesting a novel, off-target effect potentially beneficial for MCL patients with this comorbidity.

High NSD2 expression and specific mutations correlate with aggressive MCL variants, poorer treatment response, and inferior survival, establishing NSD2 as a key prognostic biomarker and potential therapeutic target.

Genomic analysis of MCL treated sequentially with BTKi and venetoclax identifies specific copy number alterations (e.g., 9p21.3 deletion) as novel biomarkers for primary and acquired resistance.

A commentary on a 40-year retrospective analysis confirms that therapeutic advances have led to gradual but significant improvements in overall survival for mantle cell lymphoma patients.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

The Endothelial Activation and Stress Index (EASIX) is a novel, independent prognostic biomarker in MCL, with high scores at diagnosis correlating with significantly shorter OS and PFS.

The SOX11:SMARCA4 complex is a key oncogenic driver in MCL, and targeting SMARCA4 with a PROTAC degrader shows preclinical activity, offering a novel therapeutic strategy for relapsed patients.

Preclinical data show CBX5 loss drives PI3Kδ inhibitor resistance in MCL, which is reversed by propolis-derived CAPE via induction of CBX5-mediated ferroptosis, a novel therapeutic strategy.

A novel para-phenylenediamine-based ROR1 inhibitor demonstrates potent preclinical activity against an MCL cell line (JeKo-1), establishing a new chemical scaffold for targeting this promising therapeutic pathway.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review summarizes recent phase II/III trial data supporting the integration of covalent BTK inhibitors into frontline MCL therapy, proposing new treatment algorithms for this setting.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

A four-decade analysis demonstrates significant, gradual overall survival improvement in MCL, validating the cumulative clinical impact of evolving therapies from chemotherapy to novel agents and transplant.

M2-polarized macrophages drive ibrutinib resistance via the CXCL5/CXCR2 axis; a CXCR2 inhibitor re-sensitizes MCL cells, suggesting a novel combination therapy to overcome BTKi resistance.

This organic chemistry paper describes a method for synthesizing complex molecules and has no direct relevance to mantle cell lymphoma clinical research, treatment, or biology.

A case of benign BCL-6-positive cutaneous mantle zone hyperplasia mimics cutaneous lymphoma, highlighting that cyclin-D1 staining remains essential to differentiate this benign entity from cutaneous mantle cell lymphoma.

This review of FDA-approved covalent inhibitors highlights the foundational role of BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) in MCL, which established this successful drug development strategy.

IGH/IGK gene rearrangement analysis improves diagnostic accuracy for B-cell lymphomas, with co-occurring IGH and IGK rearrangements being a characteristic feature of mantle cell lymphoma.

The m6A writer METTL3 promotes MCL progression by degrading Ambra1 mRNA via the reader YTHDF2, identifying a novel, potentially targetable therapeutic axis for mantle cell lymphoma.